Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.

But will the FDA accept the surrogate endpoint used in ASC4First?

This weekend’s oncology conference will feature at least 30 different ADC projects.

Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.

Early release of petosemtamab’s ASCO data suggest that analysts’ bull case has been met.

An initial winner of the ASCO abstract reveal, Verastem drops a bombshell.